ABio-X names new chief executive officer
11 November 2022 -

ABio-X, a United States-based biotech incubation platform focused on transformative medicines and breakthrough technologies, announced on Thursday that it has named Jeffrey Jonas, MD, as its new chief executive officer (CEO).

Dr Jonas has over 25 years of experience in drug development and discovery across multiple therapeutic areas in the pharmaceutical and healthcare industries.

Dr Jonas has held the position of chief innovation officer and CEO at Sage Therapeutics. He has also served as president of the Regenerative Medicine Division at Shire. He has worked as executive vice president of ISIS Pharmaceuticals and served in senior positions at Forest Laboratories, Inc. and Upjohn Laboratories.

ABio-X was founded in 2021 by CBC Group, an Asian, healthcare-dedicated asset management firm.